Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR‐mutant and EGFR‐wild type nonsquamous non‐small cell lung cancer

Documenti analoghi

• Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer
  di: Kuo, Chih‐Hsi Scott, et al.
  Pubblicazione: (2019)
• The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
  di: Hsu, Ping-Chih, et al.
  Pubblicazione: (2020)
• Unique Immune Gene Expression Patterns in Bronchoalveolar Lavage and Tumor Adjacent Non-Neoplastic Lung Tissue in Non-Small Cell Lung Cancer
  di: Kuo, Chih-Hsi Scott, et al.
  Pubblicazione: (2018)
• Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
  di: Tseng, Jeng-Sen, et al.
  Pubblicazione: (2014)
• The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations
  di: Liu, Chien-Ying, et al.
  Pubblicazione: (2017)